Perakizumab
From WikiMD's WELLNESSPEDIA
| Perakizumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 89957-37-9 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]
This drug was developed by Genentech/Roche.
References[edit]
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
- ↑ World Health Organization."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107".WHO Drug Information.2012;26(2)Full text.
| Interleukin receptor modulators | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
